Growth Metrics

Soleno Therapeutics (SLNO) Gains from Investment Securities (2013 - 2026)

Soleno Therapeutics (SLNO) reported Gains from Investment Securities of $835911.0 for Q1 2026, up 23119.75% year-over-year from N/an in Q1 2025, and up 216.58% on a QoQ basis from -$717000.0 in Q4 2025.

Soleno Therapeutics (SLNO) has 14 years of Gains from Investment Securities data on file, last reported at $835911.0 in Q1 2026.

  • Quarterly Gains from Investment Securities rose 23119.75% year-over-year to $835911.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $835911.0 (up 23119.75% YoY) and the FY2025 annual result came in at $4.0 million, up 1.52% from the prior year.
  • Gains from Investment Securities climbed to $835911.0 in Q1 2026 per SLNO's latest filing, from -$717000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $2.8 million in Q4 2024 and bottomed at -$717000.0 in Q4 2025.
  • The 5-year median for Gains from Investment Securities is $111496.5 (2022), against an average of $408823.7.
  • The widest annual swing landed in 2023, when Gains from Investment Securities tumbled 5600.0%; it then surged 108138.0% in 2024.
  • Tracing SLNO's Gains from Investment Securities over 5 years: stood at $1000.0 in 2022, then plunged by 5600.0% to -$55000.0 in 2023, then soared by 5254.55% to $2.8 million in 2024, then plunged by 125.29% to -$717000.0 in 2025, then surged by 216.58% to $835911.0 in 2026.
  • Per Business Quant, the three latest SLNO Gains from Investment Securities figures stand at $835911.0 (Q1 2026), -$717000.0 (Q4 2025), and $400000.0 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn
7 Evaxion A 64.16 Bn 64.14 Bn -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn
10 Soleno Therapeutics 2.76 Bn 2.51 Bn 93.41 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 835,911.00
Mar 31, 2026 835,911.00
Dec 31, 2025 -717,000.00
Dec 31, 2025 -717,000.00
Sep 30, 2025 400,000.00
Sep 30, 2025 400,000.00
Jun 30, 2025 300,000.00
Jun 30, 2025 300,000.00
Mar 31, 2025 3,600.00
Mar 31, 2025 3,600.00
Dec 31, 2024 2.84 Mn
Dec 31, 2024 2.84 Mn
Jun 30, 2024 1.08 Mn
Jun 30, 2024 1.08 Mn
Dec 31, 2023 -55,000.00
Dec 31, 2023 -55,000.00
Jun 30, 2023 -1,000.00
Jun 30, 2023 -1,000.00
Dec 31, 2022 1,000.00
Dec 31, 2022 1,000.00
Jun 30, 2022 219,310.00
Jun 30, 2022 219,310.00
Mar 31, 2022 3,683.00
Mar 31, 2022 3,683.00
Dec 31, 2021 461,000.00
Dec 31, 2021 461,000.00
Sep 30, 2021 -112,000.00
Sep 30, 2021 -112,000.00
Jun 30, 2021 708,750.00
Jun 30, 2021 708,750.00
Mar 31, 2021 3,938.00
Mar 31, 2021 3,938.00
Dec 31, 2020 -11.65 Mn
Dec 31, 2020 -11.65 Mn
Sep 30, 2020 689,000.00
Sep 30, 2020 689,000.00
Jun 30, 2020 -3.81 Mn
Jun 30, 2020 -3.81 Mn
Mar 31, 2020 -3.41 Mn
Mar 31, 2020 -3.41 Mn
Dec 31, 2019 6.94 Mn
Dec 31, 2019 6.94 Mn
Jun 30, 2019 4.27 Mn
Jun 30, 2019 4.27 Mn
Mar 31, 2019 21,415.00
Mar 31, 2019 21,415.00
Dec 31, 2018 -1.60 Mn
Dec 31, 2018 -1.60 Mn
Sep 30, 2018 -1.54 Mn
Sep 30, 2018 -1.54 Mn
Jun 30, 2018 3.26 Mn
Jun 30, 2018 3.26 Mn
Mar 31, 2018 82,000.00
Mar 31, 2018 82,000.00
Dec 31, 2017 490,000.00
Dec 31, 2017 490,000.00
Jun 30, 2017 610,755.00
Jun 30, 2017 610,755.00
Mar 31, 2017 12,000.00
Mar 31, 2017 12,000.00
Dec 31, 2016 274,506.00
Dec 31, 2016 274,506.00
Jun 30, 2016 11,000.00
Jun 30, 2016 11,000.00
Mar 31, 2016 19,000.00
Mar 31, 2016 19,000.00
Dec 31, 2015 2.70 Mn
Dec 31, 2015 2.70 Mn
Mar 31, 2015 500,000.00
Mar 31, 2015 500,000.00
Dec 31, 2014 8,000.00
Dec 31, 2014 8,000.00
Jun 30, 2014 238,000.00
Jun 30, 2014 238,000.00
Mar 31, 2014 -246,000.00
Mar 31, 2014 -246,000.00
Dec 31, 2013 -80,446.00
Dec 31, 2013 -80,446.00